A Study of LY900014 Compared to Insulin Lispro (Humalog) in Adults With Type 2 Diabetes
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 628 participants.
Also called NCT03952143
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 628 participants
- Sponsor
- Registry
-
NCT03952143
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- Argentina, China, Mexico
- Registry status
- Completed
Technical summary
Registry record NCT03952143. Randomized; double masking; primary purpose treatment. Start 2019-05-27 (actual); primary completion 2021-01-20 (actual). Results posted on 2022-02-08.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study of LY900014 Compared to Insulin Lispro (Humalog) in Adults With Type 2 Diabetes
- Condition
- Type 2 Diabetes Mellitus
- Intervention (Drug)
- LY900014
- Intervention (Drug)
- Insulin Lispro
- Intervention (Drug)
- Insulin Glargine
- Intervention (Drug)
- Insulin Degludec
- Lead sponsor
- Eli Lilly and Company
Record details
- Record id
cardio:ct-nct03952143- Content hash
227913a7d9b9dcf21ae7377f5d404f236b7dd5355b86d05e1c422852163a420d